CRVO

CervoMed

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 3

Sell signal 0

consensus rating "Strong Buy"

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About CRVO

Cervomed Inc.

A company that developing standard-of-care therapies for treatment-resistant solid cancerous tumors

Industry

Biological Technology

Established Date

06/18/2015

Listing Date

11/09/2016

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.cervomed.com

Security Type

Common stock

Office address

20 Park Plaza, Suite 424, Boston, Massachusetts 02116

Business

Introduction

CervoMed Inc., was incorporated in Delaware on June 18, 2015. The company is a clinical-stage biotechnology company focused on developing treatments for age-related neurological diseases.

Company Financials

EPS

CRVO has released its 2024 Q4 earnings. EPS was reported at -0.83, versus the expected -0.63, missing expectations. The chart below visualizes how CRVO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CRVO has released its 2024 Q4 earnings report, with revenue of 2.16M, reflecting a YoY change of -13.19%, and net profit of -6.71M, showing a YoY change of -183.86%. The Sankey diagram below clearly presents CRVO’s revenue sources and cost distribution.